Episode Details
Back to Episodes
FF 69:DUPLEX Sparsentan, it’s no Acthar Gel
Description
The Filtrate:
Joel Topf
Swapnil Hiremath
Priya Yenebere
Nayan Arora
With Special Guest:
Brendon Neuen Super smart guy and clinical trialist
Michelle Rheault Lead author of DUPLEX and friend of the pod
Show Notes
Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis
NephJC Summary | PubMed | NEJM
KDIGO FSGS Guidelines 2021 (PDF)
Characterization of the Clinical Evidence Supporting Repository Corticotropin Injection for FDA-Approved Indications, A Scoping Review (JAMA Internal Medicine)
DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS (PubMed)
Vlado Perkovic, mentor and sponsor extradenoire (UNSW Sydney)
Shimer Its a floor wax and a desert topping (TikTok)
SONAR: Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease: a double-blind, randomised, placebo-controlled trial. (NephJC)
Travere Therapeutics Announces FDA Accelerated Approval of FILSPARIᵀᴹ (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy (Travere press release)
GFR Slope: Chronic vs Total slope: A meta-analysis of GFR slope as a surrogate endpoint for kidney failure (Nature Medicine)
There are dozens of us! Dozens! (Know your Meme)
Brendon’s Neuen’s tweet about total versus chronic slope (X | Twitter)
Julie R. Ingelfinger, deputy editor for the New England Journal of Medicine (Wikipedia)
You know nothing, John Snow (YouTube shorts)
Listen Now
Love PodBriefly?
If you like Podbriefly.com, please consider donating to support the ongoing development.
Support Us